An observational study in Type 1 Diabetes and Child, Only, sponsored by Sheba Medical Center. Recruiting at 1 site in Israel. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Sheba Medical Center · Observational
The goal of this observational study is to describe data on Israeli children and youth using the 780G system including data regarding glycemic control parameters, various questionnaires, sleep data, bioimpedance measures, and dietary parameters. The main questions it aims to answer are: • whether the 780G system will improve glycemic control • whether the psychosocial aspects will improve. Participants will be followed once connected to 780G, at baseline, one, three, six months, 1 year, and two years after the connection.
Patients and Methods:
The study population will include individuals with type 1 diabetes ages 7-18 years who are managed by the pediatric diabetes teams from the AWeSoMe Study Group (five pediatric diabetes multidisciplinary clinics in Israel; Dana-Dwek Children's Hospital, Edmond and Lily Safra Children's Hospital, Maccabi National Juvenile Diabetes Center, Shamir Medical Center and Wolfson Medical Center) and who chose to purchase 780G out-of-pocket as part of their diabetes care, or are eligible according to the updated Israeli basket to receive it. The decision to use 780G will be made prior to and independent of their entrance to the study, and will be based on preferences of the patients and their parents.
Study design:
A prospective multi-center study (AWeSoMe Study Group) of type 1 diabetes patients using the closed-loop Medtronic 780G system as compared to their previous treatment regimen.
Data will be collected at 6 timepoints: baseline (at initiation of 780G system), after 1 month, three months and 6 months, 1 year, and 2 years of the closed-loop Medtronic 780G system usage.
Data collection:
All the data collected are available for healthcare providers (doctors, nurses and dieticians) as part of the routine diabetes clinic visit. The information retrieved from the medical files will include sociodemographic characteristics (current age, sex, socioeconomic position by home address, parent's education level, marital status of parents), anthropometric parameters (height, weight and body mass index), pubertal status, physical activity levels and diabetes-related characteristics. Diabetes-related characteristics: age at diagnosis, autoimmune co-morbidities (thyroid disease and Celiac), glycated hemoglobin (HbA1c) and acute complications (severe hypoglycemic episodes and DKA). Insulin pump and CGM downloaded data retrieved during the 2 weeks prior to the clinic visit: mode of insulin therapy (previous and current), total daily insulin dose (Units/kg/day), total daily carbohydrates (grams/day) and CGM metrics. CGM metrics will include: percent time CGM active, mean glucose level, standard deviation (SD), coefficient of variability (CV), time in range (TIR), time above range (TAR), time below range (TBR) and glucose management indicator (GMI). Closed-loop Medtronic 780G system user evaluation: reason for switching from conventional treatment to closed-loop, automode system exits and patient's/parent's perception of closed-loop system.
In addition to the data mentioned above the following data will be collected:
Questionnaires for the:
3,522 studies on the registry are indexed under Diabetes Mellitus, Type 1; 577 are open to participants now.
This study's planned enrollment of 120 is close to the median of 120 across 748 observational studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Sheba Medical Center is the lead sponsor of 660 studies on the registry; 63 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will include individuals with type 1 diabetes ages 1-21 years who are managed by the pediatric diabetes teams from the AWeSoMe Study Group (five pediatric diabetes multidisciplinary clinics in Israel; Dana-Dwek Children's Hospital, Edmond and Lily Safra Children's Hospital, Maccabi National Juvenile Diabetes Center, Shamir Medical Center and Wolfson Medical Center) and who chose to purchase 780G out-of-pocket as part of their diabetes care, or are eligible according to the updated Israeli basket to receive it. The decision to use 780G will be made prior to and independent of their entrance to the study, and will be based on preferences of the patients and their parents.
Diagnosis of type 1 diabetes Diabetes duration ≥ 6 months Routine attendance at clinic visits Initiation of 780G system usage
Exclusion Criteria:
Children under the age of 1 year Children without 780G system
Medtronic 780G® hybrid closed loop system uses the commercial "auto-mode" with an insulin pump and continuous glucose monitoring.
Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent in range (70-180 mg/dL) from baseline to three months of closed-loop Medtronic 780G system
Time frame: 0,3 months
Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent in range (70-180 mg/dL) from baseline to six months of closed-loop Medtronic 780G system
Time frame: 0,6 months
Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent in range (70-180 mg/dL) from baseline to six months of closed-loop Medtronic 780G system
Time frame: 0,12 months
Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent in range (70-180 mg/dL) from baseline to six months of closed-loop Medtronic 780G system
Time frame: 0,24 months
HbA1c as assessed from point-of-care clinic visit
Change in HbA1c from baseline to three months of closed-loop Medtronic 780G system
Time frame: 0, 3 months
HbA1c as assessed from point-of-care clinic visit
Change in HbA1c from baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 6 months
Time spent below range (≤ 70 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent below range (≤ 70 mg/dL) baseline to three months of closed-loop Medtronic 780G system
Time frame: 0, 3 months
Time spent below range (≤ 70 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent below range (≤ 70 mg/dL and ≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 6 months
Time spent below range (≤ 54 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent below range (≤ 54 mg/dL) baseline to three months of closed-loop Medtronic 780G system
Time frame: 0, 3 months
Time spent below range (≤ 54 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent below range (≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 6 months
Time spent above range (> 180 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent above range (\> 180 mg/dL) baseline to three months of closed-loop Medtronic 780G system
Time frame: 0, 3 months
Time spent above range (> 180 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent above range (\> 180 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 6 months
Time spent above range (> 250 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent above range (\> 250 mg/dL) baseline to three months of closed-loop Medtronic 780G system
Time frame: 0, 3 months
Time spent above range (> 250 mg/dL) as assessed from closed-loop Medtronic 780G system
Delta time spent above range (\> 250 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 6 months
Quality of life - child as assessed by a questionnaire
Change in quality of life - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 5, max score 100; the higher the score, the better quality of life.
Time frame: 0, 6 months
Quality of life - parent as assessed by a questionnaire
Change in quality of life - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 37, max score 185; the higher the score, the better quality of life.
Time frame: 0, 6 months
Trait anxiety - child as assessed by a questionnaire
Change in trait anxiety - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 80; the higher the score, the higher the anxiety.
Time frame: 0, 6 months
Fear of hypoglycemia - child as assessed by a questionnaire
Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.
Time frame: 0, 6 months
Fear of hypoglycemia - parent as assessed by a questionnaire
Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.
Time frame: 0, 6 months
Diabetes management - child as assessed by a questionnaire
Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.
Time frame: 0, 6 months
Diabetes management - parent as assessed by a questionnaire
Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.
Time frame: 0, 6 months
Nutrition diaries as assessed by a dietician
Change in carbohydrates grams - baseline to 6 months. Assessment of carbohydrates in grams by a certified pediatric nutritionist.
Time frame: 0, 6 months
Sleep quality as assessed by a questionnaire
Change in sleep quality - baseline to 6 months, as assessed by a validated questionnaire, as cited in the Reference section.
Time frame: 0, 6 months
HbA1c as assessed from point-of-care clinic visit
Change in HbA1c from baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 12 months
HbA1c as assessed from point-of-care clinic visit
Change in HbA1c from baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 24 months
Time spent below range (≤ 70 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent below range (≤ 70 mg/dL and ≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 12 months
Time spent below range (≤ 70 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent below range (≤ 70 mg/dL and ≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 24 months
Time spent below range (≤ 54 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent below range (≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 12 months
Time spent below range (≤ 54 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent below range (≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 24 months
Time spent above range (> 180 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent above range (\> 180 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 12 months
Time spent above range (> 180 mg/dL) as assessed from closed-loop Medtronic 780G system
Change in time spent above range (\> 180 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 24 months
Time spent above range (> 250 mg/dL) as assessed from closed-loop Medtronic 780G system
Delta time spent above range (\> 250 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 12 months
Time spent above range (> 250 mg/dL) as assessed from closed-loop Medtronic 780G system
Delta time spent above range (\> 250 mg/dL) baseline to six months of closed-loop Medtronic 780G system
Time frame: 0, 24 months
Quality of life - parent as assessed by a questionnaire
Change in quality of life - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 37, max score 185; the higher the score, the better quality of life.
Time frame: 0, 24 months
Trait anxiety - child as assessed by a questionnaire
Change in trait anxiety - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 80; the higher the score, the higher the anxiety.
Time frame: 0, 24 months
Fear of hypoglycemia - child as assessed by a questionnaire
Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.
Time frame: 0, 24 months
Fear of hypoglycemia - parent as assessed by a questionnaire
Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.
Time frame: 0, 24 months
Diabetes management - child as assessed by a questionnaire
Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.
Time frame: 0, 24 months
Diabetes management - parent as assessed by a questionnaire
Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.
Time frame: 0, 24 months
Nutrition diaries as assessed by a dietician
Change in carbohydrates grams - baseline to 6 months. Assessment of carbohydrates in grams by a certified pediatric nutritionist.
Time frame: 0, 24 months
Sleep quality as assessed by a questionnaire
Change in sleep quality - baseline to 6 months, as assessed by a validated questionnaire, as cited in the Reference section.
Time frame: 0, 24 months
Plan to share: Undecided — If requested, we will share the data collection system as needed.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sheba Medical Center